Literature DB >> 23912772

Dissociations between cognitive and motor effects of psychostimulants and atomoxetine in hyperactive DAT-KO mice.

Thomas Del'Guidice1, Morgane Lemasson, Adeline Etiévant, Stella Manta, Luiz Alexandre V Magno, Guy Escoffier, François S Roman, Jean-Martin Beaulieu.   

Abstract

RATIONALE: Psychostimulants such as amphetamine and methylphenidate, which target the dopamine transporter (DAT), are the most frequently used drugs for the treatment of hyperactivity and cognitive deficits in humans with attention deficit hyperactivity disorder (ADHD). While psychostimulants can increase activity in healthy subjects, they exert a "paradoxical" calming effect in humans with ADHD as well as in hyperactive mice lacking the dopamine transporter (DAT-KO mice). However, the mechanism of action of these drugs and their impact on cognition in the absence of DAT remain poorly understood.
OBJECTIVES: This study was conducted to investigate the effects of psychostimulants and noradrenergic and serotonergic drugs on cognition in DAT-KO mice and normal (WT) littermates.
METHODS: We used a recently developed behavioral apparatus, the automated H-maze. The H-maze involves the consecutive learning of three different rules: delayed alternation, nonalternation, and reversal tasks.
RESULTS: Treatment of WT animals with the psychostimulants replicated the behavior observed in untreated DAT-KO mice while "paradoxically" restoring cognitive performances in DAT-KO mice. Further investigation of the potential involvement of other monoamine systems in the regulation of cognitive functions showed that the norepinephrine transporter blocker atomoxetine restored cognitive performances in DAT-KO mice without affecting hyperactivity. In contrast, the nonselective serotonin receptor agonist 5CT, which antagonizes hyperactivity in DAT-KO mice, had no effect on cognitive functions.
CONCLUSIONS: Taken together, these data allow dissociation of the locomotor and cognitive effects of ADHD drugs and suggest that the combination of DAT-KO mice with the automated H-maze can constitute a powerful experimental paradigm for the preclinical development of therapeutic approaches for ADHD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23912772     DOI: 10.1007/s00213-013-3212-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  69 in total

Review 1.  Serotonin and decision making processes.

Authors:  Judith R Homberg
Journal:  Neurosci Biobehav Rev       Date:  2011-06-12       Impact factor: 8.989

2.  Nicotine improves cognitive deficits of dopamine transporter knockout mice without long-term tolerance.

Authors:  Stéphanie Weiss; Marika Nosten-Bertrand; J Michael McIntosh; Bruno Giros; Marie-Pascale Martres
Journal:  Neuropsychopharmacology       Date:  2007-03-21       Impact factor: 7.853

Review 3.  Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders.

Authors:  Amy F T Arnsten; Steven R Pliszka
Journal:  Pharmacol Biochem Behav       Date:  2011-02-02       Impact factor: 3.533

Review 4.  Therapeutic potential of 5-HT2C receptor ligands.

Authors:  Nanna H Jensen; Thomas I Cremers; Florence Sotty
Journal:  ScientificWorldJournal       Date:  2010-09-14

5.  Relationship between psychostimulant-induced "high" and dopamine transporter occupancy.

Authors:  N D Volkow; G J Wang; J S Fowler; S J Gatley; Y S Ding; J Logan; S L Dewey; R Hitzemann; J Lieberman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

6.  Characteristic neurocognitive profile associated with adult attention-deficit/hyperactivity disorder.

Authors:  A McLean; J Dowson; B Toone; S Young; E Bazanis; T W Robbins; B J Sahakian
Journal:  Psychol Med       Date:  2004-05       Impact factor: 7.723

7.  Anterior pituitary hypoplasia and dwarfism in mice lacking the dopamine transporter.

Authors:  R Bossé; F Fumagalli; M Jaber; B Giros; R R Gainetdinov; W C Wetsel; C Missale; M G Caron
Journal:  Neuron       Date:  1997-07       Impact factor: 17.173

Review 8.  Dopamine-serotonin interactions in attention-deficit hyperactivity disorder (ADHD).

Authors:  Robert D Oades
Journal:  Prog Brain Res       Date:  2008       Impact factor: 2.453

Review 9.  Dopamine transporter mutant mice in experimental neuropharmacology.

Authors:  Raul R Gainetdinov
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-05       Impact factor: 3.000

10.  Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs.

Authors:  Dawn D Han; Howard H Gu
Journal:  BMC Pharmacol       Date:  2006-03-03
View more
  14 in total

1.  Changes in the serum levels of brain-derived neurotrophic factor in adults with attention deficit hyperactivity disorder after treatment with atomoxetine.

Authors:  Josep Antoni Ramos-Quiroga; Margarida Corominas-Roso; Gloria Palomar; Nuria Gomez-Barros; Marta Ribases; Cristina Sanchez-Mora; Rosa Bosch; Mariana Nogueira; Montserrat Corrales; Sergi Valero; Miguel Casas
Journal:  Psychopharmacology (Berl)       Date:  2013-11-08       Impact factor: 4.530

Review 2.  Exploring the Validity of Proposed Transgenic Animal Models of Attention-Deficit Hyperactivity Disorder (ADHD).

Authors:  June Bryan de la Peña; Irene Joy Dela Peña; Raly James Custodio; Chrislean Jun Botanas; Hee Jin Kim; Jae Hoon Cheong
Journal:  Mol Neurobiol       Date:  2017-05-22       Impact factor: 5.590

Review 3.  Review of rodent models of attention deficit hyperactivity disorder.

Authors:  Samantha L Regan; Michael T Williams; Charles V Vorhees
Journal:  Neurosci Biobehav Rev       Date:  2021-11-27       Impact factor: 8.989

4.  Developmental Deltamethrin Exposure Causes Persistent Changes in Dopaminergic Gene Expression, Neurochemistry, and Locomotor Activity in Zebrafish.

Authors:  Tiffany S Kung; Jason R Richardson; Keith R Cooper; Lori A White
Journal:  Toxicol Sci       Date:  2015-04-24       Impact factor: 4.849

5.  Stimulation of 5-HT2C receptors improves cognitive deficits induced by human tryptophan hydroxylase 2 loss of function mutation.

Authors:  Thomas Del'Guidice; Francis Lemay; Morgane Lemasson; Jean Levasseur-Moreau; Stella Manta; Adeline Etievant; Guy Escoffier; François Y Doré; François S Roman; Jean-Martin Beaulieu
Journal:  Neuropsychopharmacology       Date:  2013-11-07       Impact factor: 7.853

6.  The Role of the Dopamine Transporter in the Effects of Amphetamine on Sleep and Sleep Architecture in Drosophila.

Authors:  Caline S Karam; Brenna L Williams; Sandra K Jones; Jonathan A Javitch
Journal:  Neurochem Res       Date:  2021-02-25       Impact factor: 3.996

7.  Effect of atomoxetine on hyperactivity in an animal model of attention-deficit/hyperactivity disorder (ADHD).

Authors:  Su Jin Moon; Chang Ju Kim; Yeon Jung Lee; Minha Hong; Juhee Han; Geon Ho Bahn
Journal:  PLoS One       Date:  2014-10-01       Impact factor: 3.240

8.  Methamphetamine-induced short-term increase and long-term decrease in spatial working memory affects protein Kinase M zeta (PKMζ), dopamine, and glutamate receptors.

Authors:  Stephen H Braren; Damian Drapala; Ingrid K Tulloch; Peter A Serrano
Journal:  Front Behav Neurosci       Date:  2014-12-18       Impact factor: 3.558

9.  Atomoxetine reduces hyperactive/impulsive behaviours in neurokinin-1 receptor 'knockout' mice.

Authors:  Katharine Pillidge; Ashley J Porter; Temis Vasili; David J Heal; S Clare Stanford
Journal:  Pharmacol Biochem Behav       Date:  2014-10-24       Impact factor: 3.533

10.  Atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report of three cases.

Authors:  Aynur Pekcanlar Akay; Gamze Capa Kaya; Burak Baykara; Yusuf Demir; Handan Özek; Sevay Alsen; Mine Sencan Eren; Neslihan Inal Emiroglu; Turkan Ertay; Yesim Ozturk; Suha Miral; Hatice Durak; Evren Tufan
Journal:  Neuropsychiatr Dis Treat       Date:  2015-11-19       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.